RxDoctor Payments Data

Bing Liu

Psychiatric/Mental Health · Clearwater, FLNPI 1609659606

Payments from drug & device makers

$6,772in general payments, 2019–2025

Across 272 payments — averaging $24.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • AbbVie$860
  • Teva Pharmaceuticals USA, Inc.$775
  • Vanda Pharmaceuticals Inc.$591
  • Alkermes, Inc.$538
  • plus $2K from 9 others

What the payments were for

  • Food & beverage$6,759100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,772 in reported general payments places this provider in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$3,715
Medicare patients
26
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate14$42,011
VraylarCariprazine Hcl21$31,440
Aripiprazole71$8,118
Lurasidone Hcl20$1,932
Oxcarbazepine21$1,908
Quetiapine Fumarate67$1,566
Hydroxyzine Hcl67$1,392
Olanzapine30$1,053
Buspirone Hcl80$851
Divalproex Sodium26$831
Bupropion XlBupropion Hcl37$689
Trazodone Hcl101$567
Divalproex Sodium ErDivalproex Sodium13$545
Venlafaxine Hcl ErVenlafaxine Hcl33$379
Lamotrigine32$376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$220$42,01114 claims
AbbVieVraylar$860$31,44021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →